Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Treatment Resistant Major Depression Disorder Clear all
Completed Phase 2 Interventional Results available

Proof of Concept Study Evaluating the Efficacy and Safety of MIJ821 in Patients With Treatment-resistant Depression

NCT03756129
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
MIJ821, Placebo, Ketamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Garden Grove, California • Oakland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 1, 2026, 9:39 AM EDT
Terminated Phase 1 Interventional

Adaptive tDCS for Treatment-Resistant MDD

NCT02942368
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
tDCS
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Recruiting Not applicable Interventional

PCS in Severe Treatment Resistant Depression

NCT04124341
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Prefrontal Cortical Stimulation (PCS)
Device
Lead sponsor
University of Minnesota
Other
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Not applicable Interventional Results available

Ketamine Infusion for Treatment-resistant Major Depressive Disorder

NCT01582945
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ketamine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 1, 2026, 9:39 AM EDT
Active, not recruiting Phase 2 Interventional

Mindfulness Engaged Neurostimulation for Depression

NCT06399406
View directory record Official record
Conditions
Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Interventions
Medi-TBS
Combination Product
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Results available

Ketamine For Suicidal Ideation

NCT01507181
View directory record Official record
Conditions
Suicidal Ideation
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of AXS-05 in Subjects With Depression

NCT04039022
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Depression
Interventions
AXS-05 (dextromethorphan and bupropion) oral tablets
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
876 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
51
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Sep 1, 2026, 9:39 AM EDT
Recruiting Phase 4 Interventional

Establishing Mobile Transcranial Magnetic Stimulation

NCT06748209
View directory record Official record
Conditions
Treatment Resistant Major Depression
Interventions
Left prefrontal Transcranial Magnetic Stimulation (TMS), FDA cleared TMS for treating depression
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
22 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional

Psilocybin rTMS for Treatment Resistant Depression

NCT06132178
View directory record Official record
Conditions
Treatment Resistant Depression, MDD, Major Depressive Disorder, Recurrent Depression, Depression
Interventions
Psilocybin, Accelerated intermittent theta burst (aiTBS) rTMS treatment, Low-dose psilocybin, Sham Accelerated intermittent theta burst (aiTBS) rTMS treatment
Drug · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 1, 2026, 9:39 AM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 1, 2026, 9:39 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Antidepressant Effects of Nitrous Oxide

NCT05357040
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 4 Interventional

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

NCT05615948
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine, Peripheral Nervous System Agents, Central Nervous System Depressants, Neurotransmitter Agents, Anti-Inflammatory Agents, Physiological Effects of Drugs, Sensory System Agents, Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-Steroidal, Depressive Symptoms
Interventions
VTS-K
Drug
Lead sponsor
Theresa Jacob, PhD, MPH
Other
Eligibility
18 Years to 89 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females

NCT02356107
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
5-hydroxytryptophan and Creatine monohydrate
Drug
Lead sponsor
Perry Renshaw
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Not applicable Interventional

A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)

NCT01909232
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator, Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator
Device
Lead sponsor
Cervel Neurotech, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Lebanon, New Hampshire + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Sep 1, 2026, 9:39 AM EDT
Withdrawn Phase 2 Interventional

N2O for Acute Suicidality and Depression in the ED

NCT05710887
View directory record Official record
Conditions
Suicidal Ideation, Major Depressive Disorder, Treatment Resistant Depression
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Not listed Phase 2 Interventional

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

NCT04971291
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
AXS-05, Bupropion SR
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

Ketamine Plus Lithium in Treatment-Resistant Depression

NCT01880593
View directory record Official record
Conditions
Depression
Interventions
Lithium, Ketamine, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 1, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder

NCT01114698
View directory record Official record
Conditions
Depression
Interventions
Venlafaxine XR, Placebo, JNJ26489112
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Arcadia, California • Escondido, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Sep 1, 2026, 9:39 AM EDT
Not yet recruiting Not applicable Interventional

One-Day cTBS Over the Precuneus

NCT07758010
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD), Treatment Resistant Major Depression Disorder
Interventions
Precuneus-targeted continuous theta-burst stimulation, Left dorsolateral prefrontal cortex intermittent theta-burst stimulation, Sham transcranial magnetic stimulation
Device
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 1, 2026, 9:39 AM EDT
Terminated Phase 2 Interventional Results available

Antidepressant Effects of TS-161 in Treatment-Resistant Depression

NCT04821271
View directory record Official record
Conditions
Major Depressive Disorder, Treatment-Resistant Depression, Depression
Interventions
Placebo, TS-161
Other · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 2 Interventional Results available

This is a Study to Determine the Antidepressant Effects of AZD6765

NCT00986479
View directory record Official record
Conditions
Treatment Resistant Major Depressive Disorder
Interventions
AZD6765, Placebo to AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Sep 1, 2026, 9:39 AM EDT
Completed Phase 4 Interventional

Effectiveness of Pramipexole for Treatment-Resistant Depression

NCT00231959
View directory record Official record
Conditions
Depression
Interventions
Pramipexole (Mirapex), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 25, 2012 · Synced Sep 1, 2026, 9:39 AM EDT
Completed No phase listed Observational

Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression

NCT06953362
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Direct Neural Electrical Stimulation
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
22 Months to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 1, 2026, 9:39 AM EDT